Cargando…

Programmed Death-Ligand 1 (PD-L1) Expression Is Induced by Insulin in Pancreatic Ductal Adenocarcinoma Cells Pointing to Its Role in Immune Checkpoint Control

SIMPLE SUMMARY: Type-2 Diabetes is an established risk factor of pancreatic cancer, yet the exact modalities as well as the contribution of hyperinsulinemia are not fully understood. In our study, we explored a possible link between insulin and the immune evasion of pancreatic cancer cells. We could...

Descripción completa

Detalles Bibliográficos
Autores principales:	Heckl, Steffen M., Mau, Franziska, Senftleben, Anke, Daunke, Tina, Beckinger, Silje, Abdullazade, Samir, Schreiber, Stefan, Röcken, Christoph, Sebens, Susanne, Schäfer, Heiner
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8293454/ https://www.ncbi.nlm.nih.gov/pubmed/34202040 http://dx.doi.org/10.3390/medsci9030048

Ejemplares similares

Hepatic myofibroblasts exert immunosuppressive effects independent of the immune checkpoint regulator PD-L1 in liver metastasis of pancreatic ductal adenocarcinoma
por: Beckinger, Silje, et al.
Publicado: (2023)

Expression and role of the immune checkpoint regulator PD-L1 in the tumor-stroma interplay of pancreatic ductal adenocarcinoma
por: Daunke, Tina, et al.
Publicado: (2023)

Insulin Receptor in Pancreatic Cancer—Crown Witness in Cross Examination
por: Heckl, Steffen M., et al.
Publicado: (2021)

Initiation of Pancreatic Cancer: The Interplay of Hyperglycemia and Macrophages Promotes the Acquisition of Malignancy-Associated Properties in Pancreatic Ductal Epithelial Cells
por: Otto, Lilli, et al.
Publicado: (2021)

Biomarkers in Liquid Biopsies for Prediction of Early Liver Metastases in Pancreatic Cancer
por: Mehdorn, Anne-Sophie, et al.
Publicado: (2022)

Sequential Treatment with Temozolomide Plus Naturally Derived AT101 as an Alternative Therapeutic Strategy: Insights into Chemoresistance Mechanisms of Surviving Glioblastoma Cells
por: Hellmold, Dana, et al.
Publicado: (2023)

Comparative Characterization of Stroma Cells and Ductal Epithelium in Chronic Pancreatitis and Pancreatic Ductal Adenocarcinoma
por: Helm, Ole, et al.
Publicado: (2014)

The anti-oxidative transcription factor Nuclear factor E2 related factor-2 (Nrf2) counteracts TGF-β1 mediated growth inhibition of pancreatic ductal epithelial cells -Nrf2 as determinant of pro-tumorigenic functions of TGF-β1
por: Genrich, Geeske, et al.
Publicado: (2016)

Impact of the Monocarboxylate Transporter-1 (MCT1)-Mediated Cellular Import of Lactate on Stemness Properties of Human Pancreatic Adenocarcinoma Cells †
por: Sandforth, Leontine, et al.
Publicado: (2020)

Questioning the IGF1 receptor’s assigned role in CRC – a case for rehabilitation?
por: Heckl, Steffen M., et al.
Publicado: (2020)

Inflammation Associated Pancreatic Tumorigenesis: Upregulation of Succinate Dehydrogenase (Subunit B) Reduces Cell Growth of Pancreatic Ductal Epithelial Cells
por: Rahn, Sascha, et al.
Publicado: (2019)

SMARCA4 and SMARCE1 in gastric cancer: Correlation with ARID1A, and microsatellite stability, and SMARCE1 / ERBB2 co‐amplification
por: Pries, Katharina, et al.
Publicado: (2023)

POLE Score: a comprehensive profiling of programmed death 1 ligand 1 expression in pancreatic ductal adenocarcinoma
por: Rahn, Sascha, et al.
Publicado: (2019)

Epithelial insulin receptor expression–prognostic relevance in colorectal cancer
por: Heckl, Steffen M., et al.
Publicado: (2018)

Rac1b negatively regulates TGF-β1-induced cell motility in pancreatic ductal epithelial cells by suppressing Smad signalling
por: Ungefroren, Hendrik, et al.
Publicado: (2013)

The novel negative checkpoint regulator VISTA is expressed in gastric carcinoma and associated with PD-L1/PD-1: A future perspective for a combined gastric cancer therapy?
por: Böger, Christine, et al.
Publicado: (2017)

PD-1 Checkpoint Inhibitor Associated Autoimmune Encephalitis
por: Schneider, Stephanie, et al.
Publicado: (2017)

How two sites of inflammation promote carcinogenesis: The role of macrophages in inflammation associated carcinogenesis
por: Sebens, Susanne, et al.
Publicado: (2012)

PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy
por: Liu, Jinhua, et al.
Publicado: (2021)

L1CAM expression in endometrial carcinomas is regulated by usage of two different promoter regions
por: Pfeifer, Marco, et al.
Publicado: (2010)

Agonist redirected checkpoint, PD1-Fc-OX40L, for cancer immunotherapy
por: Fromm, George, et al.
Publicado: (2018)

Characterization of PD-1/PD-L1 Immune Checkpoint Expression in Osteosarcoma
por: Hashimoto, Kazuhiko, et al.
Publicado: (2020)

Mycobacterial infections due to PD-1 and PD-L1 checkpoint inhibitors
por: Anand, Kartik, et al.
Publicado: (2020)

The fatal alliance of cancer and T cells: How pancreatic tumor cells gather immunosuppressive T cells
por: Grage-Griebenow, Evelin, et al.
Publicado: (2014)

The Hepatic Microenvironment and TRAIL-R2 Impact Outgrowth of Liver Metastases in Pancreatic Cancer after Surgical Resection
por: Miarka, Lauritz, et al.
Publicado: (2019)

Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma
por: Wang, Xin, et al.
Publicado: (2019)

Immunohistochemistry of immune checkpoint markers PD-1 and PD-L1 in prostate cancer
por: Sharma, Meenal, et al.
Publicado: (2019)

PD-1/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy
por: Li, Qian, et al.
Publicado: (2022)

Neoadjuvant/Perioperative Treatment Affects Spatial Distribution and Densities of Tumor Associated Neutrophils and CD8+ Lymphocytes in Gastric Cancer
por: Hoffmann, Anne, et al.
Publicado: (2021)

Cytoprotection “gone astray”: Nrf2 and its role in cancer
por: Geismann, Claudia, et al.
Publicado: (2014)

From checkpoint to checkpoint: DNA damage ATR/Chk1 checkpoint signalling elicits PD-L1 immune checkpoint activation
por: Mouw, Kent W., et al.
Publicado: (2018)

Adipose PD-L1 Modulates PD-1/PD-L1 Checkpoint Blockade Immunotherapy Efficacy in Breast Cancer
por: Wu, Bogang, et al.
Publicado: (2018)

Basal cell carcinoma: PD-L1/PD-1 checkpoint expression and tumor regression after PD-1 blockade
por: Lipson, Evan J., et al.
Publicado: (2017)

The expression of the insulin receptor in gastric cancer correlates with the HER2 status and may have putative therapeutic implications
por: Heckl, Steffen M., et al.
Publicado: (2019)

The Roles of microRNAs in Regulating the Expression of PD-1/PD-L1 Immune Checkpoint
por: Wang, Qingshui, et al.
Publicado: (2017)

Combination regimens with PD-1/PD-L1 immune checkpoint inhibitors for gastrointestinal malignancies
por: Wang, Dongxu, et al.
Publicado: (2019)

Characterization of PD-1/PD-L1 immune checkpoint expression in soft tissue sarcomas
por: Hashimoto, Kazuhiko, et al.
Publicado: (2021)

The role of PD-1/PD-L1 and application of immune-checkpoint inhibitors in human cancers
por: Tang, Qing, et al.
Publicado: (2022)

Clinicopathological assessment of PD-1/PD-L1 immune checkpoint expression in desmoid tumors
por: Hashimoto, Kazuhiko, et al.
Publicado: (2023)

Repurposing pentamidine for cancer immunotherapy by targeting the PD1/PD-L1 immune checkpoint
por: Gu, Tingxuan, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_mgftd29b1m3mnetrrp9aiaog2i